June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Resolvin-D2, a potential therapeutic strategy in retinal inflammation
Author Affiliations & Notes
  • Min Young Kim
    Eye Research Center, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States
    Eye Research Institute, Oakland University, Rochester, Michigan, United States
  • Suhani Gupta
    Eye Research Center, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States
    Eye Research Institute, Oakland University, Rochester, Michigan, United States
  • Mohamed Moustafa
    Eye Research Center, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States
    Eye Research Institute, Oakland University, Rochester, Michigan, United States
  • Ahmed Elmarakby
    Dental College of Georgia, Augusta University, Augusta, Georgia, United States
  • Mohamed Al-Sayed Al-Shabrawey
    Eye Research Center, Oakland University William Beaumont School of Medicine, Rochester, Michigan, United States
    Eye Research Institute, Oakland University, Rochester, Michigan, United States
  • Footnotes
    Commercial Relationships   Min Young Kim None; Suhani Gupta None; Mohamed Moustafa None; Ahmed Elmarakby None; Mohamed Al-Shabrawey None
  • Footnotes
    Support   Oakland University William Beaumont-School of Medicine and Oakland University Start-up and EMBARK
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3498. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Min Young Kim, Suhani Gupta, Mohamed Moustafa, Ahmed Elmarakby, Mohamed Al-Sayed Al-Shabrawey; Resolvin-D2, a potential therapeutic strategy in retinal inflammation. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3498.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : We recently demonstrated a significant increase in the circulating levels of 12/15-lipoxygenase (12/15-LO) pro-inflammatory metabolites 12- and 15-HETEs and a contrary decrease in the levels of the anti-inflammatory metabolite resolvin-D2 (RD2) in lipopolysaccharide (LPS)-treated mice. Dietary supplement of docosahexaenoic acid (DHA) restored normal levels of RD2 and attenuated LPS-induced acute kidney injury in mice. The goal of this study was to examine whether RD2 and/or DHA mitigates retinal inflammation using the LPS-induced experimental inflammation model.

Methods : Five groups of age and weight matched male wild-type (WT) mice were given the respective intraperitoneal injections: 1) saline (control), 2) LPS only (4 mg/kg), 3) LPS+RD2 (100 ng/ mouse), 4) LPS+DHA (50 mg/kg), 5) LPS+Baicalein (20 mg/kg). RD2, DHA, and baicalein, a pharmacological inhibitor of 12/15-LO, were given for 3 days before and 3 days after the single LPS injection. Additionally, three groups of age and weight matched 12/15-LO knockout (KO) mice were given the respective injections: 1) saline (control), 2) LPS (4 mg/kg), 3) LPS+DHA (50 mg/kg). DHA was given for 3 days before and 3 days after the single LPS injection. On day 7, all mice were terminated for retinal tissue collection. The mRNA expression levels of 12/15-LO, TNF-a, IL6, IL10, IL1b and ICAM-1 were analyzed with RT-PCR to determine inflammatory response levels for each group.

Results : The WT group exposed to LPS showed significant fold increase in 12/15-LO, TNF-a, ICAM-1, IL1b and modest increase in IL6 mRNA expression levels when compared to both the control group and LPS+Baicalein and LPS+DHA group. Moreover, retinal levels of IL10 were restored by baicalein and DHA. While baicalein demonstrated anti-inflammatory effect against LPS, deletion of 12/15-LO did not mitigate the effect of LPS on retinal levels of inflammatory cytokines. Additionally, RD2 abrogated the retinal levels of TNF-a
and ICAM-1 mRNA in LPS-treated mice compared to the control group.

Conclusions : RD2 and dietary supplementation of DHA are potential therapeutic interventions to treat retinal inflammatory diseases as demonstrated by decreased inflammatory markers after LPS injection. Lack of protection against LPS-induced retinal inflammation in 12/15-LO KO mice suggest that the protective effect of baicalein is independent of its 12/15-LO inhibition effect.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×